Ftse Mib
33.464,64
-0,09%
DAX
19.405,20
0,51%
S&P 500
5.987,29
0,30%
NASDAQ
19.040,77
0,20%
Bitcoin
95.009,97
-3,10%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Context Therapeutics Inc (CNTX) Context Therapeutics Inc (CNTX) Notizie

Context Therapeutics Inc

CNTX
1,495
0,105 (7,55%)
Ultimo aggiornamento: 21:42:43
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
15/11/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
14/11/202423:05EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
06/11/202422:42EDGAR2Form S-3 - Registration statement under Securities Act of..
06/11/202422:06GLOBEContext Therapeutics Reports Third Quarter 2024 Operating..
06/11/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/10/202413:30GLOBEContext Therapeutics to Participate in Upcoming Investor..
16/10/202413:30GLOBEContext Therapeutics Announces Poster Presentation at the..
23/9/202413:33EDGAR2Form 8-K - Current report
17/9/202422:22EDGAR2Form 8-K - Current report
04/9/202413:34EDGAR2Form 8-K - Current report
04/9/202413:30GLOBEContext Therapeutics Appoints Dr. Karen Smith and Dr. Luke..
07/8/202422:17GLOBEContext Therapeutics Reports Second Quarter 2024 Operating..
07/8/202422:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202423:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202423:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/8/202413:30GLOBEContext Therapeutics Appoints Chief Medical Officer and Vice..
24/7/202423:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/7/202422:55EDGAR2Form DEF 14A - Other definitive proxy statements
12/7/202422:04EDGAR2Form PRE 14A - Other preliminary proxy statements
10/7/202413:33EDGAR2Form 8-K - Current report
10/7/202413:30GLOBEContext Therapeutics Acquires Phase 1-ready T cell Engager..
14/6/202413:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202413:34EDGAR2Form 8-K - Current report
31/5/202422:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
24/5/202422:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
24/5/202413:31EDGAR2Form S-3 - Registration statement under Securities Act of..
10/5/202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/5/202422:06GLOBEContext Therapeutics Reports First Quarter 2024 Operating..
08/5/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/5/202413:31GLOBEContext Therapeutics Announces FDA Clearance of IND..
02/5/202413:30GLOBEContext Therapeutics Announces $100 Million Private..
01/4/202413:30GLOBEContext Therapeutics Submits IND Application to Evaluate..
21/3/202412:43GLOBEContext Therapeutics Reports Full Year 2023 Operating and..
06/3/202413:30EDGAR2Form 8-K - Current report
07/2/202422:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
Apertura: 1,4224 Min: 1,41 Max: 1,55
Chiusura: 1,39

La tua Cronologia

NASDAQ
CNTX
Context Therapeutics
NYSE
CRS
Carpenter Technology
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network